<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01027065</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-107-10</org_study_id>
    <secondary_id>2009-010709-35</secondary_id>
    <nct_id>NCT01027065</nct_id>
  </id_info>
  <brief_title>Dose Escalation of Interleukin-1 (IL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B Virus (HBV) Infected Patients</brief_title>
  <acronym>CONVERT</acronym>
  <official_title>A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of &quot;CYT107&quot; (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytheris SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytheris SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety of biological active dose of a new experimental&#xD;
      drug, IL-7, in combination with anti viral therapy and vaccine in patients with Hepatitis B&#xD;
      chronic infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I/IIa inter-patient dose-escalation study assessing weekly doses of&#xD;
      Interleukin-7 (CYT107) in HBeAg-negative chronic hepatitis B infected adult patients. The&#xD;
      dose escalation is aimed at establishing the safety of a biologically active doses of CYT107&#xD;
      added to the current antiviral therapy with entecavir or tenofovir and vaccination or not. At&#xD;
      each dose level, study patients will receive one subcutaneous administration of CYT107 per&#xD;
      week for a total of 4.&#xD;
&#xD;
      Groups of 8 patients will be entered at each dose level of CYT107. Three dose levels are&#xD;
      planned.&#xD;
&#xD;
      At each dose level, patients are randomized between 2 arms of treatment: tritherapy (CYT107,&#xD;
      vaccine and antiviral treatment) or bitherapy (CYT107 and vaccine). Each treatment group is&#xD;
      composed of 4 patients, 3 receiving experimental treatments, 1 just the current antiviral&#xD;
      treatment (control patient).&#xD;
&#xD;
      According to the treatment arm, eligible patients initially receive a vaccine if in treatment&#xD;
      group of tritherapy, thereafter, CYT107 is added for a cycle of four weekly injections (if&#xD;
      not a control patient) at a defined dose level. If in treatment group of tritherapy, patients&#xD;
      will receive 2 additional doses of vaccine.&#xD;
&#xD;
      The treatment phase for the tritherapy group is from first vaccine D0 to last vaccine W12 and&#xD;
      includes CYT107 administration from W4 to W7.&#xD;
&#xD;
      The treatment phase for the bitehrapy group is from W4 to W7 corresponding to CYT104&#xD;
      injections.&#xD;
&#xD;
      The patients are then followed on a regular basis until reaching 52 weeks after the D0.&#xD;
&#xD;
      Participants will have 1 overnight hospitalization and 12 clinic visit on a period of 55&#xD;
      weeks.&#xD;
&#xD;
      During the visits the following may be done:&#xD;
&#xD;
        -  medical history, physical examination, blood tests&#xD;
&#xD;
        -  electrocardiograms (ECG)&#xD;
&#xD;
        -  chest X-Ray&#xD;
&#xD;
        -  liver/spleen imaging&#xD;
&#xD;
        -  urine tests&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the short and long-term safety and biological activity of CYT107 in patients with a HBeAg-negative chronic hepatitis B who have, at screening a HBV DNA undetectable stable for at least 3 months with antiviral treatment.</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics and pharmacodynamics of CYT107 in humans chronically infected with HBV.</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the effects of the tri-therapy (CYT107 + HBV vaccine + antiviral treatment) versus bi-therapy (CYT107 + antiviral treatment) versus control (antiviral treatment) on the markers of the HBV infection (antiviral activity)at W16 weeks and W52</measure>
    <time_frame>Week 12 and Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To quantify the effects of the tri-therapy (CYT107 + HBV vaccine + antiviral treatment) versus bi-therapy (CYT107 + antiviral treatment) versus control (antiviral treatment) on the immune system at W16 weeks</measure>
    <time_frame>Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Tritherapy: CYT107+ vaccine+ antiviral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bitherapy: CYT107 + antiviral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT107+GenHevac+entecavir or tenofovir</intervention_name>
    <description>4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment</description>
    <arm_group_label>Tritherapy: CYT107+ vaccine+ antiviral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYT107+ entecavir or tenofovir</intervention_name>
    <description>4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment</description>
    <arm_group_label>Bitherapy: CYT107 + antiviral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic HBV-infected patients&#xD;
&#xD;
          -  HBeAg-negative patients&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Patients with active chronic hepatitis at the start of the antiviral treatment&#xD;
&#xD;
          -  Patient with a HBV DNA undetectable (&lt;70 copies/ml) stable for at least 3 months under&#xD;
             entecavir or tenofovir treatment.&#xD;
&#xD;
          -  Ongoing treatment by entecavir or tenofovir at screening Note: previous treatment with&#xD;
             pegylated IFN monotherapy, before the start of entecavir or tenofovir, is acceptable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infection by HCV&#xD;
&#xD;
          -  Infection by HIV-1 and /or HIV-2&#xD;
&#xD;
          -  Apart from HBV infection, presence of active infection requiring a specific treatment&#xD;
             or a hospitalization&#xD;
&#xD;
          -  Previous treatment by lamivudine and/or nucleosides analogues&#xD;
&#xD;
          -  Inactive carrier&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  Other liver disease (notably from alcoholic, metabolic or immunological origin)&#xD;
&#xD;
          -  History of clinical autoimmune disease or active auto-immune disease&#xD;
&#xD;
          -  Type I diabetes mellitus&#xD;
&#xD;
          -  Severe asthma, presently on chronic medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Hezode</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Henri Mondor-Cr√©teil-France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pietro Andreone</last_name>
    <role>Principal Investigator</role>
    <affiliation>S. Orsola Malpighi- Bologna-Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Henri Mendor-Service d'HepatoGastroEnterologie</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Hotel Dieu</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU l'Archet</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Civil</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria, Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>December 4, 2009</study_first_submitted>
  <study_first_submitted_qc>December 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2009</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interleukin-7</keyword>
  <keyword>immune-based therapies</keyword>
  <keyword>hepatitis B</keyword>
  <keyword>HBe negative</keyword>
  <keyword>HBV vaccination</keyword>
  <keyword>entecavir</keyword>
  <keyword>tenofovir</keyword>
  <keyword>chronic hepatitis</keyword>
  <keyword>immune specific responses to HBV</keyword>
  <keyword>phase 1/2a</keyword>
  <keyword>viral disease</keyword>
  <keyword>liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

